首页
开始购物
.0

banner

启动持续优惠Keep ON通行证 马上节省10%以及运费优惠
最近观看

START ON

ampk activation

产品特点

启动新陈代谢:激活 AMPK 代谢开关 魔力蛋白 逆龄代谢

肌肉细胞中的 AMPK上调52%,脂肪细胞中的 AMPK上调300%

科研参考 Scientific journal reference: Adaptive Medicine 5(4): 181-188, 2013 181 DOI: 10.4247/AM.2013.ABD068

糖尿病管理与调节血糖:减少胰岛素抵抗

脂肪细胞中的脂联素上调 103%,胰岛素抵抗脂肪细胞中的脂联素上调 248%

脂联素提升代表着身体在燃烧脂肪。脂联素是一种细胞信使,在肝脏中发挥作用,调节细胞葡萄糖摄取和脂肪燃烧。 

科研参考 Scientific journal reference: Journal of Biochemistry and Biotechnology, vol. 4, no. 5, 29 Aug. 2021, pp. 1–8

燃烧脂肪 : 提升脂肪细胞内ACC燃脂酶

ACC是脂肪细胞内负责调节脂肪代谢与燃烧的一种生物酶

科研参考 Scientific journal reference: Adaptive Medicine 5(4): 181-188, 2013

我们备有专利配方与及强大的科研团队 临床研究证明产品安全高效

资料参考

  • Bartlett, Jacquelaine, et al. “Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?” Circulation: Cardiovascular Quality and Outcomes, vol. 9, no. 3, May 2016, pp. 206–212, 10.1161/circoutcomes.115.002436; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871717/
  • Wang, T. D., et al. “Efficacy of Cholesterol Levels and Ratios in Predicting Future Coronary Heart Disease in a Chinese Population.” The American Journal of Cardiology, vol. 88, no. 7, 1 Oct. 2001, pp. 737–743, 10.1016/s0002-9149(01)01843-4; https://pubmed.ncbi.nlm.nih.gov/11589839
  • McLaughlin, Tracey, et al. “Use of Metabolic Markers to Identify Overweight Individuals Who Are Insulin Resistant.” Annals of Internal Medicine, vol. 139, no. 10, 18 Nov. 2003, p. 802, 10.7326/0003-4819-139-10-200311180-00007; https://pubmed.ncbi.nlm.nih.gov/14623617/
  • Buhl, Esben S, et al; “Long-Term AICAR Administration Reduces Metabolic Disturbances and Lowers Blood Pressure in Rats Displaying Features of the Insulin Resistance Syndrome.”; Diabetes; U.S. National Library of Medicine; July 2002; https://www.ncbi.nlm.nih.gov/pubmed/12086950/
  • Entezari, Maliheh et al. “AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2022): 112563. doi:10.1016/j.biopha.2021.112563; https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(21)01350-0
  • Srikanthan, Krithika et al; “Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.”; International journal of medical sciences; vol. 13,1; 25-38; 1 Jan. 2016; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716817/
  • Lihn, A S, et a;. “Adiponectin: Action, Regulation and Association to Insulin Sensitivity.;” Obesity Reviews : an Official Journal of the International Association for the Study of Obesity; U.S. National Library of Medicine; Feb. 2005; https://www.ncbi.nlm.nih.gov/pubmed/15655035
  • Stolic, M, et al. “Glucose Uptake and Insulin Action in Human Adipose Tissue—Influence of BMI, Anatomical Depot and Body Fat Distribution.” International Journal of Obesity, vol. 26, no. 1, Jan. 2002, pp. 17–23, 10.1038/sj.ijo.0801850. https://www.nature.com/articles/0801850
  • Berg, Jeremy M; “Acetyl Coenzyme A Carboxylase Plays a Key Role in Controlling Fatty Acid Metabolism.”; Biochemistry. 5th Edition; U.S. National Library of Medicine; 1 Jan. 1970; https://www.ncbi.nlm.nih.gov/books/NBK22381/
  • ‌Alam, Fahmida et al. “Metabolic Control of Type 2 Diabetes by Targeting the GLUT4 Glucose Transporter: Intervention Approaches.” Current pharmaceutical design vol. 22,20 (2016): 3034-49. doi:10.2174/1381612822666160307145801 https://www.eurekaselect.com/140253/article
  • Ralser, M., et al. “A Catabolic Block Does Not Sufficiently Explain How 2-Deoxy-D-Glucose Inhibits Cell Growth.” Proceedings of the National Academy of Sciences, vol. 105, no. 46, 11 Nov. 2008, pp. 17807–17811, 10.1073/pnas.0803090105 https://www.pnas.org/doi/10.1073/pnas.0803090105
  • Kim, Ji Hye et al. “Role of ginsenosides, the main active components of Panax ginseng, in inflammatory responses and diseases.” Journal of ginseng research vol. 41,4 (2017): 435-443. doi:10.1016/j.jgr.2016.08.004; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628327/
  • Danne, Thomas, et al; “Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.”; Diabetes Technology & Therapeutics; U.S. National Library of Medicine; June 2018; https://www.ncbi.nlm.nih.gov/pubmed/29916741
  • Chang, Tsu-Chung, et al. “Effect of Ginsenosides on Glucose Uptake in Human Caco-2 Cells Is Mediated through Altered Na+/Glucose Cotransporter 1 Expression.” Journal of Agricultural and Food Chemistry, vol. 55, no. 5, Mar. 2007, pp. 1993–1998, 10.1021/jf062714k; https://pubmed.ncbi.nlm.nih.gov/17269785/
  • Ziello, Jennifer E et al; “Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia.”; The Yale journal of biology and medicine; vol. 80,2; 2007; 51-60; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2140184/
  • He, Qing et al. “Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia.” American journal of physiology. Endocrinology and metabolism vol. 300,5 (2011): E877-85. doi:10.1152/ajpendo.00626.2010; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3093977/
  • Zhang, Silin et al. “Ginsenoside Compound K Regulates HIF-1α-Mediated Glycolysis Through Bclaf1 to Inhibit the Proliferation of Human Liver Cancer Cells.” Frontiers in pharmacology vol. 11 583334. 8 Dec. 2020, doi:10.3389/fphar.2020.583334; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753211/
  • Gwozdziewiczová, Simona, et al; “TNF-Alpha in the Development of Insulin Resistance and Other Disorders in Metabolic Syndrome.”; Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia; U.S. National Library of Medicine; June 2005; https://www.ncbi.nlm.nih.gov/pubmed/16170397
  • Lee, Davy C W, and Allan S Y Lau. “Effects of Panax ginseng on tumor necrosis factor-α-mediated inflammation: a mini-review.” Molecules (Basel, Switzerland) vol. 16,4 2802-16. 30 Mar. 2011, doi:10.3390/molecules16042802; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260618/
  • Cesari, Matteo et al; “Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.”; Cardiovascular therapeutics; vol. 28,5; 2010; e72-91; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958211/

启动您的 AMPK 魔力蛋白 逆龄代谢

CN
产品已添加到您的购物车